2-fluoro-6-(2,2,2-trifluoroethoxy)benzaldehyde | 907609-06-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-fluoro-6-(2,2,2-trifluoroethoxy)benzaldehyde
• 英文别名: 2-Fluoro-6-(2,2,2-trifluoroethoxy)benzaldehyde
• CAS: 907609-06-7
• 化学式: C₉H₆F₄O₂
• 分子量: 222.139
• InChiKey: QNQWATWCTLTYSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-氟--6-(2,2,2-三氟乙氧基)苯腈 在 二异丁基氢化铝 、 甲醇 、 盐酸 、 水 、 碳酸氢钠 作用下， 以 甲苯 为溶剂， 反应 16.17h， 以94%的产率得到2-fluoro-6-(2,2,2-trifluoroethoxy)benzaldehyde
  参考文献：
  名称：

  WO2006/90224

  摘要：

  公开号：

文献信息

• Palladium-Catalyzed Dehydrogenative Fluoroalkoxylation of Benzaldehydes
  作者：Long Jin、Xing-Long Zhang、Rui-Li Guo、Meng-Yue Wang、Ya-Ru Gao、Yong-Qiang Wang

  DOI：10.1021/acs.orglett.1c00365

  日期：2021.3.5

  A direct and efficient palladium-catalyzed oxidative dehydrogenative fluoroalkoxylation of benzaldehydes is reported here for the first time. The method features mild reaction conditions, good tolerance of functional groups, and a broad substrate scope. The protocol employs the transient directing group strategy, thereby avoiding the additional installation and removal of directing groups, endowing

  首次报道了直接有效的钯催化的苯甲醛氧化脱氢氟烷氧基化反应。该方法具有温和的反应条件，对官能团的良好耐受性以及广泛的底物范围。该协议采用瞬态指导基团策略，从而避免了额外的安装和去除指导基团，使该方法具有原子和步骤经济的巨大优势。该方法应在药物合成和发现过程中找到广泛的应用。
• NOVEL PYRROLOPYRIMIDINE COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, ESPECIALLY AGENT FOR PREVENTION AND/OR TREATMENT OF TUMORS ETC BASED ON NAE INHIBITORY EFFECT
  申请人：TAIHO PHARMACEUTICAL CO., LTD.

  公开号：US20170066772A1

  公开（公告）日：2017-03-09

  An object to be solved by the present invention is to provide a novel pyrrolopyrimidine compound or a salt thereof having an NAE inhibitory action and a cell growth inhibitory effect. The present invention provides a compound or a salt thereof represented by Formula (A), as well as an NAE inhibitor, a pharmaceutical composition, and an antitumor agent comprising the compound or a salt thereof as an active ingredient.

  本发明要解决的问题是提供一种具有NAE抑制作用和细胞生长抑制作用的新型吡咯吡嘧啶化合物或其盐。本发明提供了由化学式（A）表示的化合物或其盐，以及一种NAE抑制剂、含有该化合物或其盐作为活性成分的药物组合物和抗肿瘤剂。
• Benzisoxazole Derivatives
  申请人：Noguchi Hirohide

  公开号：US20080207690A1

  公开（公告）日：2008-08-28

  This invention relates to compounds of the formula (I): wherein A, B, R 1 , R 4 , m, and n are each as described herein or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT 4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central 10 nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.

  本发明涉及化合物的公式（I）：其中A，B，R1，R4，m和n分别如本文所述或其药学上可接受的盐，并包含这些化合物的组合物以及这些化合物在治疗由5-HT4受体活性介导的疾病中的使用，例如但不限于胃食管反流病，胃肠道疾病，胃动力障碍，非溃疡性消化不良，功能性消化不良，肠易激综合症（IBS），便秘，消化不良，食管炎，胃食管疾病，恶心，中枢神经系统疾病，阿尔茨海默病，认知障碍，呕吐，偏头痛，神经系统疾病，疼痛，心血管疾病，如心力衰竭和心律失常，糖尿病和呼吸暂停综合症。
• Benzisoxazole derivatives
  申请人：Noguchi Hirohide

  公开号：US08816090B2

  公开（公告）日：2014-08-26

  This invention relates to compounds of the formula (I): wherein A, B, R1, R4, m, and n are each as described herein or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central 10 nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.

  本发明涉及式(I)的化合物，其中A、B、R1、R4、m和n分别如本文所述或其药学上可接受的盐，以及含有此类化合物的组合物和利用此类化合物治疗由5-HT4受体活性介导的疾病，例如但不限于胃食管反流病、胃肠疾病、胃动力障碍、非溃疡性消化不良、功能性消化不良、肠易激综合征（IBS）、便秘、消化不良、食管炎、胃食管疾病、恶心、中枢神经系统疾病、阿尔茨海默病、认知障碍、呕吐、偏头痛、神经系统疾病、疼痛、心血管疾病如心力衰竭和心律失常、糖尿病和呼吸暂停综合征。
• ANTITUMOR EFFECT POTENTIATOR COMPRISING PYRROLOPYRIMIDINE COMPOUND
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP3395345A1

  公开（公告）日：2018-10-31

  Disclosed is an antitumor effect potentiator for one or more other compounds having an antitumor effect, the antitumor effect potentiator comprising a novel pyrrolopyrimidine compound.

  本发明公开了一种用于一种或多种具有抗肿瘤效果的其他化合物的抗肿瘤效果增效剂，该抗肿瘤效果增效剂包括一种新型吡咯并嘧啶化合物。